Signs and symptoms vary in severity depending upon factors such as the amount of drug absorbed, the age of the patient, and the time elapsed since drug ingestion. Critical manifestations of overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic toxicity. In U.S. clinical trials, 2 deaths occurred in 12 reported cases of acute overdosage with Anafranil either alone or in combination with other drugs. One death involved a patient suspected of ingesting a dose of 7000 mg. The second death involved a patient suspected of ingesting a dose of 5750 mg.
Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression.
Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
Patients with this genotype have reduced metabolism of clomipramine.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.
The presence of this polymorphism in CYP2C19 is associated with poor metabolism of clomipramine.
The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of clomipramine.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Clomipramine. |
| Duloxetine | The risk or severity of orthostatic hypotension and syncope can be increased when Clomipramine is combined with Duloxetine. |
| Levodopa | The risk or severity of hypotension and orthostatic hypotension can be increased when Clomipramine is combined with Levodopa. |
| Risperidone | Clomipramine may increase the hypotensive activities of Risperidone. |
| Cilostazol | The serum concentration of Cilostazol can be increased when it is combined with Clomipramine. |
| Citalopram | The serum concentration of Citalopram can be increased when it is combined with Clomipramine. |
| Deferasirox | The serum concentration of Clomipramine can be increased when it is combined with Deferasirox. |
| Flibanserin | The serum concentration of Flibanserin can be increased when it is combined with Clomipramine. |
| Peginterferon alfa-2b | The serum concentration of Clomipramine can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Clomipramine can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Clomipramine can be decreased when it is combined with Teriflunomide. |
| Valsartan | Clomipramine may decrease the antihypertensive activities of Valsartan. |
| Ramipril | Clomipramine may decrease the antihypertensive activities of Ramipril. |
| Remikiren | Clomipramine may decrease the antihypertensive activities of Remikiren. |
| Guanadrel | Clomipramine may decrease the antihypertensive activities of Guanadrel. |
| Olmesartan | Clomipramine may decrease the antihypertensive activities of Olmesartan. |
| Minoxidil | Clomipramine may decrease the antihypertensive activities of Minoxidil. |
| Trandolapril | Clomipramine may decrease the antihypertensive activities of Trandolapril. |
| Benazepril | Clomipramine may decrease the antihypertensive activities of Benazepril. |
| Candoxatril | Clomipramine may decrease the antihypertensive activities of Candoxatril. |
| Nitroglycerin | Clomipramine may decrease the antihypertensive activities of Nitroglycerin. |
| Cryptenamine | Clomipramine may decrease the antihypertensive activities of Cryptenamine. |
| Candesartan cilexetil | Clomipramine may decrease the antihypertensive activities of Candesartan cilexetil. |
| Tolazoline | Clomipramine may decrease the antihypertensive activities of Tolazoline. |
| Eprosartan | Clomipramine may decrease the antihypertensive activities of Eprosartan. |
| Quinapril | Clomipramine may decrease the antihypertensive activities of Quinapril. |
| Omapatrilat | Clomipramine may decrease the antihypertensive activities of Omapatrilat. |
| Phenoxybenzamine | Clomipramine may decrease the antihypertensive activities of Phenoxybenzamine. |
| Deserpidine | Clomipramine may decrease the antihypertensive activities of Deserpidine. |
| Terazosin | Clomipramine may decrease the antihypertensive activities of Terazosin. |
| Rescinnamine | Clomipramine may decrease the antihypertensive activities of Rescinnamine. |
| Cilazapril | Clomipramine may decrease the antihypertensive activities of Cilazapril. |
| Saprisartan | Clomipramine may decrease the antihypertensive activities of Saprisartan. |
| Spirapril | Clomipramine may decrease the antihypertensive activities of Spirapril. |
| Dexpropranolol | Clomipramine may decrease the antihypertensive activities of Dexpropranolol. |
| Diethylnorspermine | Clomipramine may decrease the antihypertensive activities of Diethylnorspermine. |
| Temocapril | Clomipramine may decrease the antihypertensive activities of Temocapril. |
| Indoramin | Clomipramine may decrease the antihypertensive activities of Indoramin. |
| Trimazosin | Clomipramine may decrease the antihypertensive activities of Trimazosin. |
| Rauwolfia serpentina root | Clomipramine may decrease the antihypertensive activities of Rauwolfia serpentina root. |
| Angiotensin 1-7 | Clomipramine may decrease the antihypertensive activities of Angiotensin 1-7. |
| Imidapril | Clomipramine may decrease the antihypertensive activities of Imidapril. |
| BQ-123 | Clomipramine may decrease the antihypertensive activities of BQ-123. |
| Zofenopril | Clomipramine may decrease the antihypertensive activities of Zofenopril. |
| Guanoxan | Clomipramine may decrease the antihypertensive activities of Guanoxan. |
| Delapril | Clomipramine may decrease the antihypertensive activities of Delapril. |
| Vincamine | Clomipramine may decrease the antihypertensive activities of Vincamine. |
| Linsidomine | Clomipramine may decrease the antihypertensive activities of Linsidomine. |
| Guanoxabenz | Clomipramine may decrease the antihypertensive activities of Guanoxabenz. |
| Tolonidine | Clomipramine may decrease the antihypertensive activities of Tolonidine. |
| Endralazine | Clomipramine may decrease the antihypertensive activities of Endralazine. |
| Cadralazine | Clomipramine may decrease the antihypertensive activities of Cadralazine. |
| Bietaserpine | Clomipramine may decrease the antihypertensive activities of Bietaserpine. |
| Guanazodine | Clomipramine may decrease the antihypertensive activities of Guanazodine. |
| Methoserpidine | Clomipramine may decrease the antihypertensive activities of Methoserpidine. |
| Guanoclor | Clomipramine may decrease the antihypertensive activities of Guanoclor. |
| Candesartan | Clomipramine may decrease the antihypertensive activities of Candesartan. |
| Tocopherylquinone | Clomipramine may decrease the antihypertensive activities of Tocopherylquinone. |
| Benazeprilat | Clomipramine may decrease the antihypertensive activities of Benazeprilat. |
| Fosinoprilat | Clomipramine may decrease the antihypertensive activities of Fosinoprilat. |
| Ramiprilat | Clomipramine may decrease the antihypertensive activities of Ramiprilat. |
| Perindoprilat | Clomipramine may decrease the antihypertensive activities of Perindoprilat. |
| Quinaprilat | Clomipramine may decrease the antihypertensive activities of Quinaprilat. |
| Enalapril | Clomipramine may decrease the antihypertensive activities of Enalapril. |
| Captopril | Clomipramine may decrease the antihypertensive activities of Captopril. |
| Pinacidil | Clomipramine may decrease the antihypertensive activities of Pinacidil. |
| Riociguat | Clomipramine may decrease the antihypertensive activities of Riociguat. |
| Aliskiren | Clomipramine may decrease the antihypertensive activities of Aliskiren. |
| Naftopidil | Clomipramine may decrease the antihypertensive activities of Naftopidil. |
| Dexniguldipine | Clomipramine may decrease the antihypertensive activities of Dexniguldipine. |
| Prazosin | Clomipramine may decrease the antihypertensive activities of Prazosin. |
| Ambrisentan | Clomipramine may decrease the antihypertensive activities of Ambrisentan. |
| Selexipag | Clomipramine may decrease the antihypertensive activities of Selexipag. |
| Nitroprusside | Clomipramine may decrease the antihypertensive activities of Nitroprusside. |
| Amlodipine | The metabolism of Clomipramine can be decreased when combined with Amlodipine. |
| Nisoldipine | Clomipramine may decrease the antihypertensive activities of Nisoldipine. |
| Fosinopril | Clomipramine may decrease the antihypertensive activities of Fosinopril. |
| Bisoprolol | Clomipramine may decrease the antihypertensive activities of Bisoprolol. |
| Phentolamine | Clomipramine may decrease the antihypertensive activities of Phentolamine. |
| Lisinopril | Clomipramine may decrease the antihypertensive activities of Lisinopril. |
| Perindopril | Clomipramine may decrease the antihypertensive activities of Perindopril. |
| Fenoldopam | Clomipramine may decrease the antihypertensive activities of Fenoldopam. |
| Tadalafil | Clomipramine may decrease the antihypertensive activities of Tadalafil. |
| Guanethidine | Clomipramine may decrease the antihypertensive activities of Guanethidine. |
| Epoprostenol | Clomipramine may decrease the antihypertensive activities of Epoprostenol. |
| Macitentan | Clomipramine may decrease the antihypertensive activities of Macitentan. |
| Enalaprilat | Clomipramine may decrease the antihypertensive activities of Enalaprilat. |
| Levamlodipine | Clomipramine may decrease the antihypertensive activities of Levamlodipine. |
| Lercanidipine | Clomipramine may decrease the antihypertensive activities of Lercanidipine. |
| Diazoxide | Clomipramine may decrease the antihypertensive activities of Diazoxide. |
| Buprenorphine | Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine. |
| Hydrocodone | Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Clomipramine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Clomipramine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clomipramine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Clomipramine. |